RxDoctor Payments Data

Moses Kitakule, MD

Pulmonary Disease · New Iberia, LANPI 1588602056

Payments from drug & device makers

$5,050in general payments, 2019–2025

Across 290 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Regeneron Healthcare Solutions, Inc.$552
  • Sanofi$448
  • AstraZeneca$379
  • Actelion Pharmaceuticals US, Inc.$343
  • Amgen$157
  • plus $995 from 17 others

What the payments were for

  • Food & beverage$4,99999%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,050 in reported general payments places this provider in the 50th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$236,205
Medicare patients
1,082
Services billed
3,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter978$800,463
Breo ElliptaFluticasone/Vilanterol688$327,185
Fasenra PenBenralizumab34$203,492
Breztri AerosphereBudesonide/Glycopyr/Formoterol167$117,266
SymbicortBudesonide/Formoterol Fumarate378$112,238
Spiriva HandihalerTiotropium Bromide158$97,806
XolairOmalizumab13$72,018
FasenraBenralizumab12$68,268
Incruse ElliptaUmeclidinium Bromide105$40,744
Ambrisentan12$38,823
BreynaBudesonide/Formoterol Fumarate168$35,216
Spiriva RespimatTiotropium Bromide66$34,762
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr67$32,735
Stiolto RespimatTiotropium Br/Olodaterol Hcl55$28,685
Albuterol Sulfate HfaAlbuterol Sulfate945$27,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$2,176$1,205,4401,849 claims
AstraZenecaBreztri Aerosphere, Symbicort, Fasenra$379$297,772557 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$137$86,173163 claims
MerckDulera$81$13,68536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 189 pulmonary disease providers in Louisiana.

Other pulmonary disease in New Iberia

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →